<DOC>
	<DOCNO>NCT02521376</DOCNO>
	<brief_summary>The primary objective study evaluate pharmacokinetics Entospletinib ( ENTO ) and/or metabolite ( applicable ) participant impaired hepatic function ( stratify smoking status , appropriate ) relative match , healthy control .</brief_summary>
	<brief_title>Pharmacokinetics Entospletinib Adults With Normal Impaired Liver Function</brief_title>
	<detailed_description />
	<criteria>Calculated body mass index 18 40 kg/m^2 Not pregnant Normal electrocardiogram Participants impair liver function must sufficiently healthy base upon medical history physical examination , vital sign , screen laboratory evaluation . Participation another clinical study ( current within last 30 day ) HIV , hepatitis B virus , active hepatitis C virus infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>